All In Biotech

Drug Trial Radar · NCT05947071

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

Comparison of High vs Standard Dose Influenza Vaccines in Pediatric Solid Organ Transplant Recipients

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 312 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

312

Planned (sponsor's estimate)

Start

Sep 26, 2024

Primary completion

Jul 1, 2027

Study completion Sep 1, 2027

Sponsor

Sponsor type
NIH
First posted
Jul 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Influenza virus is a significant pathogen in pediatric solid organ transplant (SOT) recipients. However, these individuals respond poorly to standard-dose (SD) inactivated influenza vaccine (IIV). Recent studies have investigated two strategies to overcome poor immune responses in SOT recipients: (1) administration of high-dose (HD)-IIV compared to SD-IIV and (2) two doses of SD-IIV compared to one dose of SD-IIV in the same influenza season. One study compared HD-IIV vs. SD-IIV in adult SOT recipients and noted that HD-IIV was safe and more immunogenic; however, the median post-transplant period was 38 months. A phase I pediatric study comparing a single dose of HD-IIV vs. SD-IIV was safe with higher immunogenicity, but the study was limited by small sample size and median post-transplant vaccine administration was 26 months. In another phase II trial of adult SOT recipients, two doses of SD-IIV one month apart compared to one-dose of SD-IIV revealed modestly increased immunogenicity when given at a median of 18 months post-transplant. Therefore, these studies lack both evaluation in the early post-transplant period and substantive pediatric populations. Additionally, the administration of two-doses of HD-IIV in the same influenza season has not been evaluated in pediatric SOT recipients. Thus, the optimal immunization strategy for pediatric SOT recipients less than 24 months post-transplant is unknown. In addition, immunologic predictors and correlates of influenza vaccine immunogenicity in pediatric SOT recipients have not been well-defined. The central hypothesis of our proposal is that pediatric SOT recipients 1-23 months post-transplant who receive two doses of HD-quadrivalent inactivated influenza vaccine (QIV) will have similar safety but higher Hemagglutination Inhibition (HAI) geometric mean titers (GMTs) to influenza antigens compared to pediatric SOT recipients receiving two doses of SD-QIV.

Conditions

  • Immunization; Infection
  • Transplantation Infection
  • Influenza

Interventions

  • Standard Dose Quadrivalent Inactivated Influenza VaccineBiological

    Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.

  • High Dose Quadrivalent Inactivated Influenza VaccineBiological

    Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a "split virus". The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Immunogenicity: Hemagglutination Inhibition (HAI) titersTime frame: 4 weeks following the 2nd study vaccine
  2. Safety: solicited local and systemic post-administration reactionsTime frame: in the first 7 days following each study vaccine

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Stanford, California · Recruiting

  • Children's Healthcare of Atlanta

    Atlanta, Georgia · Recruiting

  • Ann Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois · Recruiting

  • Indiana University School of Medicine/Riley Hospital for Children

    Indianapolis, Indiana · Recruiting

  • Children's Mercy Hospital

    Kansas City, Missouri · Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

  • Monroe Carell Jr. Children's Hospital at Vanderbilt

    Nashville, Tennessee · Recruiting

  • Texas Children's Hospital

    Houston, Texas · Recruiting

  • Seattle Children's

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.